QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 16 August 2023Portfolio NewsImbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
- 7 August 2023Portfolio NewsIkena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
- 27 June 2023Portfolio NewsMestag Therapeutics and VIB enter into an exclusive partnership in oncology
- 14 June 2023Portfolio NewsEyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema
- 13 June 2023Portfolio NewsAutifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)
- 9 June 2023Portfolio NewsUK cell therapy start-up agrees AstraZeneca partnership worth up to $2bn
- 9 June 2023Portfolio NewsQuell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
- 8 June 2023Portfolio NewsPulmocide Announces Expansion of Management Team
- 5 June 2023Portfolio NewsImbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
- 31 May 2023Portfolio NewsCumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer's Dementia Validation Trial
- 31 May 2023Portfolio NewsViolet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Ventures (MGBV)
- 15 May 2023Portfolio NewsTherini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease